Skip to main content
. Author manuscript; available in PMC: 2020 Jan 24.
Published in final edited form as: Pharmacogenomics J. 2019 Feb 4;19(6):528–537. doi: 10.1038/s41397-019-0076-2

Figure 1. Patient-Reported Discussions Surrounding Medication Changes: Pharmacogenomically-Influenced Medication Change Visits vs. Traditional Medication Change Visits.

Figure 1.

Percentage of medication change visits where patients reported discussions of specific topics, including “individual prescribing factors”, “genetics/DNA”, “specific genetic test results”, and/or a “better prescribing decision” due to use of a specific genetic test result. For statistical comparison, case traditional medication change visits were combined with control medication change visits as there were no statistically significant differences between the two groups. This group was then compared to pharmacogenomically-influenced medication change visits. The “n” value represents the total number of visits analyzed for each question. Patients who had pharmacogenomically-influenced medication changes significantly more often reported discussions of “individual prescribing factors” OR=10.1 [3.3–31.0], p<0.0001; “genetics/DNA” OR=41.5 [9.5–182.8], p<0.0001; “specific genetic test result” OR=30.3 [6.2–148.4], p<0.0001; and “better prescribing decision” OR=27.4 [12.4–60.8], p<0.0001 compared to all non-pharmacogenomically-influenced medication changes (case traditional + control).